Reagent and Library Prep Kit Bundles Available for the MiniSeq System

Order your MiniSeq reagents and library prep kits together for additional savings and convenience. Select item 20005610 and add to your cart.

TruSight Tumor 15

Focused sequencing panel to assess 15 genes that are commonly mutated in solid tumors in a single assay, with a simple, rapid workflow. Read More...
Select Product(s)

TruSight Tumor 15 MiSeq Kit

OP-101-1001

Price
 
 

TruSight Tumor 15 (Library Prep Only)

OP-101-1002

Price
 
 

TruSight Tumor 15 MiniSeq Kit

20005610

Price
 
 

Product Highlights

TruSight Tumor 15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. It accurately detects low-frequency variants from 20 ng of starting DNA and is optimized for formalin-fixed, paraffin-embedded (FFPE) tumor tissue.

View the Gene List

Featuring a rapid workflow that can be easily integrated into lab procedures, this panel offers a single assay for accurate, economical, and rapid analysis of solid tumors.

This TruSight Tumor panel offers:

  • Comprehensive workflow: Assess 15 genes with one simple workflow instead of single, iterative gene testing with polymerase chain reaction (PCR)
  • Efficient: Rapid turnaround with only 3.5 hours of hands-on time, going from DNA to data in approximately 36 hours
  • Relevant gene content for solid tumors: Somatic variants selected from relevant industry guidelines1, key opinion leaders2,3, and pharmaceutical research
  • Sensitive variant detection from low DNA input: Accurate somatic variant detection of 5% allele frequency using 20 ng DNA from FFPE tissue samples
TruSight Tumor 15 Sample Datasets

3 human reference samples and 5 FFPE-exacted DNA samples from lung, colon, melanoma, and breast tumors were prepared using TruSight Tumor 15. These libraries were sequenced on the MiniSeq System using a high output kit at a 2 x 150 bp read length configuration with dual indexing. The total yield was 7.6 Gb with 94.9% of bases at or above Q30.

Browse the data in BaseSpace Sequence Hub:

Access to this data requires a BaseSpace Sequence Hub login.
Register for BaseSpace Sequence Hub

See All Cancer Research Panels

Frequently Purchased Together

Specifications

Project Recommendations

Instrument Recommended Number of Samples Read Length
MiniSeq System Samples per run: mid output: 2-3, high output: 8 (based on 93.5% of the bases covered at 500x minimum) 2 × 150 bp (max recommended)
MiSeq System 8 samples per run with v3 reagents (based on 93.5% of the bases covered at 500x minimum) 2 × 151 bp (max recommended)

Method-Specific Workflow Example

 
TruSight Tumor 15 Gene List
AKT1 GNA11 NRAS
BRAF GNAQ PDGFRA
EGFR KIT PIK3CA
ERBB2 KRAS RET
FOXL2 MET TP53

Kit requires MiSeq Software v2.6 or higher and the Illumina Annotation Engine. Download files

Related Products

References
  1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1-9.
  2. Rousseau B, Jacquot C, Le Palabe J, et al. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in non-small cell lung cancer treatment. Sci Rep. 2015;5:10356.
  3. Haley L, Tseng LH, Zheng G, et al. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers [published online July 31 2015]. Mod Pathol. 2015. doi: 10.1038/modpathol.2015.86.